HOUSTON, TEXAS May 19, 2009. Pharm-Olam International Ltd. (POI) a global, full service CRO to pharmaceutical and biotech industries has closed enrollment on a hematology study involving several thousand patients. The study was a phase IV registry and involved POI covering 13 countries and over 130 sites worldwide. POI worked closely with the study sponsor to determine their needs and capabilities in each country and formed a cost effective plan for conducting the trial.
“We have noticed sponsors’ concerns over the economic climate and understand their need to leverage internal resources and outsourcing effectively. Pharm-Olam is a privately-held global CRO which has a profitable history and a strong stable balance sheet. We strive to satisfy our clients with coverage in over 40 countries and full service capabilities. With our global footprint and financial stability Pharm-Olam is an ideal strategic partner for any sponsor”, said John Hovre, Chief Operating Officer.
POI’s recent strategic outsourcing enhancements include:
Office Locations – relocated to larger offices in Belgrade, Serbia and Milan, Italy and opened a new office in St. Petersburg, Russia to complement existing coverage in Moscow and Novosibirsk.
Pharmacovigilance – addition of global electronic adverse event management and reporting to regulatory agencies.
Data Management – Interactive Web Response as part of our EDC system made available as a more cost effective alternative to IVRS randomization and supply management. Tech transfers from new ASP providers allow sponsors more flexibility in choosing a data management system.
Regulatory – additional full time regulatory specialists added in Latin America. POI can now submit regulatory documents directly to Mexico’s MoH and serve as the drug importer, reducing timelines for start-up.
For more information about Pharm-Olam please contact John Hovre, Chief Operating Officer at john.hovre@pharm-olam.com.
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. POI differentiates itself by having more local coverage than most of its competitors in Eastern Europe, Russia, Ukraine and Georgia. POI operated in those countries for more than 10 years and in the last 5 years in India, Western Europe, South Africa, South America, Mexico, USA and Canada.
